Urofollitropin

Urofollitropin

Clinical data
Trade names	Bravelle, Fertinex
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Pregnancy category	US: X (Contraindicated)
Legal status	US: ℞-only
Routes of administration	Subcutaneous, intramuscular
Identifiers
CAS Number	146479-72-3 Y
ATC code	G03GA04 (WHO)
PubChem	CID: 62819
IUPHAR/BPS	1157
DrugBank	DB00094 N
UNII	W9BB98U6HP N
KEGG	D06400 Y
ChEMBL	CHEMBL1201520 N
Chemical data
Formula	C975H1513N267O304S26
Molecular mass	22672.9 g/mol
NY (what is this?)  (verify)

Urofollitropin is a purified form of follicle-stimulating hormone (FSH) that is manufactured by extraction from human urine and then purified to remove various proteins and other substances. FSH is important in the development of follicles (eggs) produced by the ovaries. Given by subcutaneous injection, it is used in combination with human chorionic gonadotropin (hCG) to assist in ovulation and fertility. It is also used with in vitro fertilization methods. The dosage is adjusted to each individual's response.

The most common side effects are abdominal or pelvic pain, bloating, as well as redness, pain or swelling at the injection site. Follitropin is possibly associated with increased risk of endometrial carcinoma. It is not for use during pregnancy, as there is evidence for birth defects under follitropin treatment.

Bravelle sold in the United States from March 2014 through October 2015 is subject to a recall and refund by its maker, Ferring Pharmaceuticals, because certain batches of the medicine had a lower strength than stated.

External links

• Bravelle, by Ferring Pharmaceuticals, Switzerland
• Fostimon by Institut Biochemique SA, Switzerland